Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Rice to the rescue: new study tests Low-GI, High-Protein rice for diabetes prevention

NCT ID NCT07663123

Disease control Sponsor: Institute for Human Development and Potential (IHDP), Singapore Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 16, 2026 · Updated 2 times

Summary

The HARVEST study is testing whether eating a special low-glycemic, high-protein rice instead of regular white rice can improve blood sugar control in people with prediabetes or type 2 diabetes. Over 16 weeks, 225 adults in Singapore will replace their usual rice with one of three types: regular white rice, low-GI rice, or low-GI high-protein rice. The goal is to see if this simple swap can lower HbA1c levels and help prevent diabetes.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
functional rice varieties (low glycemic index and high protein rice)
What this could lead to
If successful, this could provide a simple, culturally acceptable way to help manage blood sugar and prevent progression to type 2 diabetes without major diet changes.
What could go wrong
This is a relatively small, early-stage trial (225 participants) and results may not apply to other populations. The rice is a dietary supplement, not a drug, so effects may be modest.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 225 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2026

An estimate. Start dates often move.

Expected to finish

Apr 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

40 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Males or females, aged 40 to 65 years old 2. Chinese, Malay or Indian 3. Body Mass Index between 23.0 - 32.0 kg/m2 4. Prediabetes profile as per fasting plasma glucose (≤ 6.9 mmol/L) and HbA1c level (5.7% - 6.4%) 5. Habitually consuming about 3 to 5 servings of polished white rice per day 6. No known food allergies and intolerance to food provided as part of study procedures 7. Proficient in English language 8. Willing to comply to study procedures and provide written consent Exclusion Criteria: 1. Diagnosed with Type 1 or 2 diabetes mellitus/ OGTT failure during screening visit 2. History or current diagnosis of cardiovascular, endocrine, gastrointestinal, haematological, hepatitis (hepatitis B and C), cancers (except basal cell carcinoma), chronic kidney disease or other medical conditions which may affect study outcomes, as assessed by study team 3. Having chronic medication (eg: metformin, oral corticosteroids etc), and/or supplements that may influence glycaemic management and other study outcomes, as assessed by study team 4. History of bariatric surgery 5. Significant weight change (± 5 % body weight) during the last 3 months 6. Women who are pregnant, breastfeeding or planning pregnancy 7. Drug abuse within the last 5 years 8. Excessive alcohol consumption \> 2 servings per day 9. Smoking in the last 1 year 10. Following any special diet(s) which may interfere with study outcomes (eg: Ketogenic diet, intermittent fasting, calorie-deficit) 11. Major change in physical activity and/or dietary habits in the last 3 months 12. Use of oral antibiotics in the last 3 months 13. Participation in other intervention studies, which may affect study outcomes as assessed by study team 14. Staff of IHDP and SIFBI in A\*STAR

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Prediabetes / type 2 diabetes are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

prediabetes syndrome type 2 diabetes mellitus prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Prediabetes / type 2 diabetes

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.